Landiolol, an ultrashort-acting β1-adrenoceptor antagonist, has protective effects in an lps-induced systemic inflammation model

Shock

Volumn 31, Issue 5, 2009, Pages 515-520

  Hagiwara, Satoshi ^a   Iwasaka, Hideo ^a   Maeda, Hayato ^a   Noguchi, Takayuki ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

adrenoceptor blocking agent; High mobility group box 1; Inflammation; LPS; Sepsis

Indexed keywords

CYTOKINE; ENDOTOXIN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LANDIOLOL; LIPOPOLYSACCHARIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DRUG DERIVATIVE; HBP1 PROTEIN, RAT; INTERLEUKIN 6; MORPHOLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UREA;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRY WEIGHT; HEART DISEASE; HEART FUNCTION; HEART FUNCTION TEST; HEART PROTECTION; HISTOPATHOLOGY; INFLAMMATION; LUNG PARENCHYMA; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SEPSIS; SIGNAL TRANSDUCTION; TISSUE LEVEL; ANIMAL; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; HEART RATE; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; LUNG; METABOLISM; PATHOLOGY; WESTERN BLOTTING; WISTAR RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; HEART RATE; HEMODYNAMICS; HMGB1 PROTEIN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LUNG; MALE; MORPHOLINES; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA; UREA;

EID: 67649342816     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181863689     Document Type: Article

References (43)

1. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554, 2003.
2. Schlichting D, McCollam JS: Recognizing and managing severe sepsis: a common and deadly threat. South Med J 100:594-600, 2007.
3. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulmé R, et al.: Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 28:108-121, 2002.
4. Rudiger A, Singer M: Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 35(6):1599-1608, 2007.
5. Costa EL, Schettino IA, Schettino GP: The lung in sepsis: guilty or innocent? Endocr Metab Immune Disord Drug Targets 6:213-216, 2006.
6. McDonoughKH, Virag JI: Sepsis-induced myocardial dysfunction and myocardial protection from ischemia/reperfusion injury. Front Biosci 11:23-32, 2006.
7. Kessler W, Traeger T, Westerholt A, Neher F, Mikulcak M, Müller A, Maier S, Heidecke CD: The vagal nerve as a link between the nervous and immune system in the instance of polymicrobial sepsis. Langenbecks Arch Surg 391: 83-87, 2006.
8. Iguchi S, Iwamura H, Nishizaki M, Hayashi A, Senokuchi K, Kobayashi K, Sakaki K, Hachiya K, Ichioka Y, Kawamura M: Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101. Chem Pharm Bull (Tokyo) 40:1462-1469, 1992.
9. Motomura S, Hagihara A, Narumi Y, Hashimoto K: Time course of a new ultrashort-acting β- adrenoceptor-blocking drug, ONO-1101: comparison with those of esmolol and propranolol by using the canine isolated, blood-perfused heart preparations. J Cardiovasc Pharmacol 31:431-440, 1998.
10. Chi DS, Fitzgerald SM, Pitts S, Cantor K, King E, Lee SA, Huang SK, Krishnaswamy G: MAPK-dependent regulation of IL-1- and β-adrenoceptor- induced inflammatory cytokine production from mast cells: implications for the stress response. BMC Immunol 5:22, 2004.
11. Le Tulzo Y, Shenkar R, Kaneko D, Moine P, Fantuzzi G, Dinarello CA, Abraham E: Hemorrhage increases cytokine expression in lung mononuclear cells in mice: involvement of catecholamines in nuclear factor-kappaB regulation and cytokine expression. J Clin Invest 99:1516-1524, 1997.
12. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H: HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26:174-179, 2006.
13. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, et al.: High Mobility Group Box 1 protein (HMGB1) interacts with multiple Toll like receptors. Am J Physiol Cell Physiol 290:917-924, 2006.
14. Ueno H, Matsuda T, Hashimoto S, Amaya F, Kitamura Y, Tanaka M, Kobayashi A, Maruyama I, Yamada S, Hasegawa N, et al.: Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 170:1310-1316, 2004.
15. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, FrazierA, Yang H, Ivanova S, Borovikova L, et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-251, 1999.
16. Hagiwara S, Iwasaka H, Uchino T, Noguchi T: High Mobility Group Box 1 induces a negative inotropic effect on the left ventricle in an isolated rat heart model of septic shock: a pilot study. Circ J 72:1012-1017, 2008.
17. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ: HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 164:1768-1773, 2001.
18. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, et al.: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088, 1998.
19. Li Q, Verma IM: NF-kappaB regulation in the immune system. Nat Rev Immunol 2:725-734, 2002.
20. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S, et al.: High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 48:971-981, 2003.
21. Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, TraceyKJ: Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 126: 389-392, 1999.
22. Liu SF, Malik AB: NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 290(4): L622-L645, 2006.
23. Murakami K, McGuire R, Cox RA, Jodoin JM, Bjertnaes LJ, Katahira J, Traber LD, Schmalstieg FC, Hawkins HK, Herndon DN, et al.: Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 18:236-241, 2002.
24. Meng X, Brown JM, Ao L, Nordeen SK, Franklin W, Harken AH, Banerjee A: Endotoxin induces cardiac HSP70 and resistance to endotoxemic myocardial depression in rats. Am J Physiol 271(4 Pt 1):C1316-C1324, 1996.
25. Brown MA, Jones WK: NF-kappaB action in sepsis: the innate immune system and the heart. Front Biosci 9:1201-1217, 2004.
26. Meng X, Brown JM, Ao L, Banerjee A, Harken AH: Norepinephrine induces cardiac heat shock protein 70 and delayed cardioprotection in the rat through 1 adrenoceptors. Cardiovasc Res 32:374-383, 1996.
27. Zhang H, Kim YK, Govindarajan A, Baba A, Binnie M, Marco Ranieri V, Liu M, Slutsky AS: Effect of adrenoceptors on endotoxin-induced cytokines and lipid peroxidation in lung explants. Am J Respir Crit Care Med 160: 1703-1710, 1999.
28. Takashima S, Schlidt SA, Koukoulis G, Sevala M, Egan TM: Isoproterenol reduces ischemia-reperfusion lung injury despite beta-blockade. J Surg Res 126(1):114-120, 2005.
29. Bhatia M, Moochhala S: Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol 202:145-156, 2004.
30. Court O, Kumar A, Parrillo JE, Kumar A: Clinical review: myocardial depression in sepsis and septic shock. Crit Care 6:500-508, 2002.
31. Zhang H, Wang HY, Bassel-Duby R, Maass DL, Johnston WE, Horton JW, Tao W: Role of interleukin-6 in cardiac inflammation and dysfunction after burn complicated by sepsis. Am J Physiol Heart Circ Physiol 292: H2408-H2416, 2007.
32. Duncan DJ, Hopkins PM, Harrison SM: Negative inotropic effects of tumour necrosis factor-alpha and interleukin-1beta are ameliorated by alfentanil in rat ventricular myocytes. Br J Pharmacol 150:720-726, 2007.
33. Suzuki T, Morisaki H, Serita R, Yamamoto M, Kotake Y, Ishizaka A, Takeda J: Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med 33:2294-2301, 2005.
34. Izeboud CA, Monshouwer M, van Miert AS, Witkamp RF: The beta-adrenoceptor agonist clenbuterol is a potent inhibitor of the LPS-induced production of TNF-alpha and IL-6 in vitro and in vivo. Inflamm Res 48(9):497-502, 1999.
35. Izeboud CA, Mocking JA, Monshouwer M, van Miert AS, Witkamp RF: Participation of beta-adrenergic receptors on macrophages in modulation of LPS-induced cytokine release. J Recept Signal Transduct Res 19(1-4): 191-202, 1999.
36. Izeboud CA, Hoebe KH, Grootendorst AF, Nijmeijer SM, van Miert AS, Witkamp RR, Rodenburg RJ: Endotoxin-induced liver damage in rats is minimized by beta 2-adrenoceptor stimulation. Inflamm Res 53(3):93-99, 2004.
37. Nakamura A, Johns EJ, Imaizumi A, Yanagawa Y, Kohsaka T: Beta(2)-adrenoceptor agonist suppresses renal tumour necrosis factor and enhances interleukin-6 gene expression induced by endotoxin. Nephrol Dial Transplant 15(12):1928-1934, 2000.
38. Palumbo R, Galvez BG, Pusterla T, De Marchis F, Cossu G, Marcu KB, Bianchi ME: Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-{kappa}B activation. J Cell Biol 179:33-40, 2007.
39. Arnalich F, Garcia-Palomero E, Lopez J, Jimenez M, Madero R, Renart J, Vazquez JJ, Montiel C: Predictive value of nuclear factor kappaB activity and plasma cytokine levels in patients with sepsis. Infect Immun 68:1942-1945, 2000.
40. Bohrer H, Qiu F, Zimmermann T, Zhang Y, Jllmer T, Mannel D, Bottiger BW, Stern DM, Waldherr R, Saeger HD, et al.: Role of NFkappaB in the mortality of sepsis. J Clin Invest 100:972-985, 1997.
41. Pritts TA, Moon MR, Wang Q, Hungness ES, Salzman AL, Fischer JE, Hasselgren PO: Activation of NF-kappaB varies in different regions of the gastrointestinal tract during endotoxemia. Shock 14:118-122, 2000.
42. Yang SP, Ho LJ, Lin YL, Cheng SM, Tsao TP, Chang DM, Hsu YL, Shih CY, Juan TY, Lai JH: Carvedilol, a new antioxidative beta-blocker, blocks in vitro human peripheral blood T cell activation by downregulating NF-kappaB activity. Cardiovasc Res 59:776-787, 2003.
43. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP, Arnold B, Bianchi ME, Manfredi AA, Rovere-Querini P: Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 174:7506-7515, 2005.